Advertisement

Topics

Merck Files Six SBLAs To Update Dosing Frequency For KEYTRUDA

07:28 EDT 9 Jul 2019 | FinanzNachrichten

KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) said the FDA has accepted for review six supplemental Biologics License Applications (sBLAs) to update the dosing frequency for KEYTRUDA, to include an ever...

Original Article: Merck Files Six SBLAs To Update Dosing Frequency For KEYTRUDA

NEXT ARTICLE

More From BioPortfolio on "Merck Files Six SBLAs To Update Dosing Frequency For KEYTRUDA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...